2019
Applied Clinical Research in Hematological Malignancies
<
Cancer Programme
Group Leader
Antonio Salar Silvestre
The group is mainly interested in the study of myeloproliferative neoplasms and lymphomas. We are now studying molecular markers in chronic myeloproliferative neoplasms, mainly driver mutations but also mutations in epigenetic modifiers and genes involved in the splicing mechanism, and their role in monitoring the response to cytoreductive therapy and in patient outcome.
In addition, the group is searching for new mutations using exome sequencing techniques in patients with essential thrombocythemia unmutated for JAK2, CALR and MPL genes. Moreover, the role of circulating DNA as a tool to diagnose and monitor the response to therapy in myeloid neoplasms is an ongoing research project.
Another area of research is the use of NGS and circulating DNA to study the diagnostic and prognostic role of mutations in B-cell neoplasms (diffuse large B-cell lymphomas and follicular lymphoma). We are focused in analyzing the relationship of these molecular biomarkers with response to therapy and outcome.
Another area of clinical research in lymphoma focuses on the usefulness of natriuretic peptides and cardiovascular risk scales for predicting anthracycline-induced cardiomyotoxicity in patients with lymphomas.
Research group
Members
Eugenia Abella Monreal (Researcher)
Beatriz Bellosillo Paricio (Researcher)
Eva Gimeno Vázquez (Researcher)
Carmen Jiménez Martínez (Researcher)
Blanca Sánchez González (Researcher)
Nieves García Gisbert (PhD Student)
Lierni Fernández Ibarrondo (Technician)
Francesc Garcia Pallarols (Technician)
Joan Gibert Fernández (Technician)
María Elena Torres Grande (Technician)
Main Publications
• Bellosillo B, Montagut C. High-accuracy liquid biopsies. Nat Med 2019; 25(12): 1820-1821. IF 30.641. Q1.
• Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C. Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy. Ann Oncol 2019; 30(3): 439-446. IF 14.196. D1.
• Ferraro MP, Gimeno-Vázquez E, Subirana I, Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, Martínez L, Ble M, Molina L, Belarte LC, Abella E, Elosua R, Comín-Colet J, Salar A. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur J Haematol 2019; 102(6): 509-515. IF 2.217. Q3.
Ongoing Research Projects
• Mutation characterization and tumor mutational burden in early progressor follicular lymphoma.
- Financing institution: Gilead grant (GLD18/00117)
- Period: from 2019 to 2021
- Principal investigator: Salar Silvestre, Antonio
Clinical Trials Signed in 2019
• A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Protocol: BGB-3111-305
- Sponsor: BeiGene, Ltd.
- Budget: 41,587.5 €
- Principal investigator: Gimeno Vázquez, Eva
• Estudio de fase 2, abierto y de un solo grupo, del inhibidor de HDAC oral abexinostat en pacientes con linfoma folicular en recaída o refractario
- Protocol: XYN-601
- Sponsor: Xynomic Pharmaceuticals
- Budget: 13,099.2 €
- Principal investigator: Salar Silvestre, Antonio
• Estudio multicéntrico, abierto y de un solo grupo de “Gazyva” en infusión de corta duración (ICD) en pacientes con linfoma folicular avanzado no tratado previamente
- Protocol: MO40597
- Sponsor: Roche Farma S.A.
- Budget: 19,496 €
- Principal investigator: Salar Silvestre, Antonio
• Estudio en fase I, multicéntrico y abierto para evaluar la seguridad, tolerabilidad y farmacocinética de dosis crecientes de RO7082859, administradas después de una dosis única fija de obinutuzumab (Gazyva®/Gazyvaro™), a pacientes con linfoma no Hodgkin de linfocitos B recidivante/resistente
- Protocol: NP30179
- Sponsor: Roche Farma S.A.
- Budget: 94,230 €
- Principal investigator: Salar Silvestre, Antonio
• Treatment with Daratumumab in relapsed / refractory Multiple Myeloma patients in clinical care practice in Catalonia. A retrospective study
- Protocol: GEM-DAR-2018-01
- Sponsor: Grup per a l'Estudi del Mieloma Múltiple i l’Amiloïdosi de Catalunya (GEMMAC)
- Budget: No economic compensation
- Principal investigator: Abella Monreal, Eugenia
• Un estudio retrospectivo de observación de cohortes sobre la monoterapia con lenalidomida en el linfoma difuso de células B grandes refractario o recidivante (LDCBG RR) para generar un control histórico para el Ensayo clínico MOR208C203
- Protocol: MOR208C206
- Sponsor: MorphoSys AG
- Budget: 1,500 €
- Principal investigator: Salar Silvestre, Antonio
• A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
- Protocol: AFM13-202
- Sponsor: Affimed GMBH
- Budget: 109,821.95€
- Principal investigator: Sánchez González, Blanca
Awards
• Eugenia Abella Monreal. Impacto de la incorporación de un Gestor de Casos en el diagnóstico y seguimiento de pacientes con Mieloma Múltiple Sintomático. 3rd edition of the Innovation in the Area of Health Award. Universidad de Alcalá de Henares. March 2019.
Appointments
• Antonio Salar Silvestre. GELTAMO Group Treasurer.
Outreach
Conferences, Seminars and Courses
• Antonio Salar. Moderator and speaker. Simposium Congreso SEHH. València, 25 October 2019.
• Antonio Salar. Speaker. 1st Azerbaijan International Congress of Hematology Specialist. Azerbaijan, 22-25 May 2019.
• Beatriz Bellosillo. Teacher. Curso online de Biopsia líquida. March 2019.
• Beatriz Bellosillo. Speaker. MPN&MPNr-EuroNet XIVth Workshop. Belgrado, Serbia, 8-10 May 2019.
• Blanca Sánchez-González. Guía GELTAMO de linfoma de Hodgkin 2019. ISBN: 978-84-09-11251-7.
Dissemination to Society and Initiatives of Citizen Participation
• Blanca Sánchez-González. Coordinator. Jornada para pacientes con PTI. Barcelona, 7 May 2019.
• Beatriz Bellosillo. Què representa per a l’investigador posar en marxa el seu projecte de recerca gràcies a la suma d’esforços dels donants a La Marató, la primera iniciativa solidària del país? Masterclass of the La Marató de TV3. Campus Hospital del Mar, 9 April 2019.
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es